Drug
Naratriptan
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Red Blood Cell Sedimentation Rate Increased | 24 | 33.2 | 33.8 | signal |
| 2 | Oesophagitis | 18 | 25.2 | 25.6 | signal |
| 3 | Lymphocyte Count Decreased | 26 | 22.5 | 23.0 | signal |
| 4 | Subarachnoid Haemorrhage | 14 | 21.0 | 21.2 | signal |
| 5 | Blood Lactate Dehydrogenase Increased | 20 | 19.2 | 19.5 | signal |
| 6 | Migraine | 117 | 18.9 | 20.6 | signal |
| 7 | Gamma-glutamyltransferase Increased | 21 | 14.5 | 14.7 | signal |
| 8 | Blood Alkaline Phosphatase Increased | 22 | 13.6 | 13.8 | signal |
| 9 | Hepatitis | 21 | 12.6 | 12.8 | signal |
| 10 | C-reactive Protein Increased | 22 | 9.3 | 9.4 | signal |
| 11 | Eyelid Ptosis | 6 | 9.0 | 9.1 | signal |
| 12 | Dystonia | 11 | 8.7 | 8.7 | signal |
| 13 | Renal Pain | 5 | 7.3 | 7.3 | signal |
| 14 | Product Physical Issue | 9 | 6.9 | 7.0 | signal |
| 15 | Abscess | 7 | 6.7 | 6.8 | signal |
| 16 | Increased Tendency To Bruise | 4 | 6.6 | 6.7 | signal |
| 17 | Impaired Work Ability | 9 | 6.4 | 6.5 | signal |
| 18 | Inflammatory Bowel Disease | 4 | 6.2 | 6.2 | signal |
| 19 | Therapeutic Product Effect Decreased | 18 | 6.2 | 6.3 | signal |
| 20 | Scratch | 4 | 5.9 | 5.9 | signal |
| 21 | Sleep Disorder Due To A General Medical Condition | 6 | 5.7 | 5.7 | signal |
| 22 | Serotonin Syndrome | 7 | 5.6 | 5.6 | signal |
| 23 | Bipolar Disorder | 4 | 5.6 | 5.6 | signal |
| 24 | Product Substitution Issue | 20 | 5.3 | 5.4 | signal |
| 25 | Agranulocytosis | 6 | 5.0 | 5.0 | signal |
| 26 | Personality Change | 3 | 4.9 | 4.9 | signal |
| 27 | Therapeutic Response Shortened | 10 | 4.8 | 4.8 | signal |
| 28 | Euphoric Mood | 3 | 4.5 | 4.5 | signal |
| 29 | Foetal Exposure During Pregnancy | 23 | 4.3 | 4.4 | signal |
| 30 | Underdose | 19 | 4.0 | 4.0 | signal |
| 31 | Injection Site Rash | 7 | 3.5 | 3.5 | signal |
| 32 | Dysmenorrhoea | 3 | 3.5 | 3.5 | no signal |
| 33 | Product Taste Abnormal | 3 | 3.4 | 3.4 | no signal |
| 34 | Injection Site Urticaria | 5 | 3.2 | 3.2 | signal |
| 35 | Injury Associated With Device | 4 | 3.0 | 3.1 | no signal |
| 36 | Premature Baby | 6 | 3.0 | 3.1 | signal |
| 37 | Injection Site Pruritus | 12 | 2.8 | 2.8 | signal |
| 38 | Complication Of Device Removal | 3 | 2.7 | 2.7 | no signal |
| 39 | Multiple Sclerosis Relapse | 12 | 2.7 | 2.7 | signal |
| 40 | Withdrawal Syndrome | 7 | 2.5 | 2.5 | signal |
| 41 | Injection Site Bruising | 13 | 2.5 | 2.5 | signal |
| 42 | Suicide Attempt | 10 | 2.5 | 2.5 | signal |
| 43 | Drug Effect Incomplete | 6 | 2.5 | 2.5 | no signal |
| 44 | Injection Site Mass | 6 | 2.5 | 2.5 | no signal |
| 45 | Injection Site Reaction | 11 | 2.5 | 2.5 | signal |
| 46 | Incorrect Dose Administered By Device | 4 | 2.4 | 2.4 | no signal |
| 47 | Skin Irritation | 7 | 2.3 | 2.3 | signal |
| 48 | Menstruation Irregular | 4 | 2.3 | 2.3 | no signal |
| 49 | Multiple Sclerosis | 7 | 2.2 | 2.2 | no signal |
| 50 | Intentional Overdose | 9 | 2.2 | 2.2 | signal |
| 51 | Dermatitis Atopic | 7 | 2.1 | 2.2 | no signal |
| 52 | Exposure Via Skin Contact | 3 | 2.0 | 2.0 | no signal |
| 53 | Injection Site Haemorrhage | 10 | 1.9 | 1.9 | no signal |
| 54 | Injection Site Erythema | 15 | 1.9 | 1.9 | no signal |
| 55 | Injection Site Swelling | 9 | 1.8 | 1.8 | no signal |
| 56 | Breast Cancer Female | 3 | 1.7 | 1.7 | no signal |
| 57 | Accidental Exposure To Product | 11 | 1.7 | 1.7 | no signal |
| 58 | Device Breakage | 3 | 1.2 | 1.2 | no signal |
| 59 | Device Difficult To Use | 5 | 1.2 | 1.2 | no signal |
| 60 | Wrong Technique In Device Usage Process | 3 | 1.0 | 1.0 | no signal |
| 61 | Drug Dose Omission By Device | 5 | 1.0 | 1.0 | no signal |
| 62 | Drug Dependence | 9 | 0.8 | 0.8 | no signal |